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I. LIST OF ABBREVIATIONS 
 
 
AEC   3-amino-9-ethylcarbazole 
APC   adenomatosus polyposis coli 
bFGF   basic fibroblast growth factor 
BMP   bone morphogenetic protein 
BRCA   breast cancer 
bZIP   basic-leucine zipper 
CamK   Ca++/calmodulin dependent protein kinase 
CBA   cytometric bead array 
Cdc42   cell division control protein homolog 42 
ChIP   chromatin immunoprecipitation 
DABCO  1, 4-diazabicyclo [2.2.2] octane 
DAG   diacyl glycerol 
Dkk   Dickkopf 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DTT   dithiothreitol 
Dvl   dishevelled 
EGF   epidermal growth factor 
EGTA   ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
ERK   extracellular signal-regulated kinase 
FAK   focal adhesion kinase 
Fzd   frizzled 
γC   common gamma chain 
gp130   glycoprotein 130 
GPI   glycosyl-phosphatidyl-inositol 
GSK-3ß  glycogen synthase kinase 3 beta 
GTPase  guanine triphosphatase 
HB-EGF  heparin-binding EGF-like growth factor 
hCG   human chorionic gonadotropin 
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HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
hPL   human placental lactogen 
HRPO   horse radish peroxidase 
IGF   insulin-like growth factor 
IL-4R  interleukin-4 receptor alpha 
IRS   insulin receptor substrate 
JAK   Janus kinase 
JNK   c-Jun N-terminal kinase 
KLF-5   Kruppel-like factor-5 
LEF   lymphoid enhancer binding factor 
Leu Zip  leucine zipper 
LPS   lipopolisaccharide 
LRP   low-density lipoprotein receptor-related protein 
LTR   long terminal repeat 
MAPK  mitogen-activated protein kinase 
MAPKK  mitogen-activated protein kinase kinase 
MAPKKK  mitogen-activated protein kinase kinase kinase 
MβCD   methyl- β-cyclodextrin 
MMP   matrix metalloproteinase 
NK   natural killer 
NLS   nuclear localization signal 
ORF   open reading frame 
PAK   p21 activated kinase 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PE   phycoerythrin 
PHA   phytohemagglutinin 
PIBF   progesterone-induced blocking factor 
PIBFR   PIBF-receptor 
PMSF   phenylmethylsulfonyl fluoride 
PI3K   phosphoinositide 3-kinase 
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PIP2   phosphatidylinositol 4,5-bisphosphate 
PIP3   phosphatidylinositol 3,4,5-triphosphate 
PI-PLC  phosphatidylinositol-specific phospholipase C 
PKC   protein kinace C 
PlGF   placental growth factor 
PLC   phospholipase C 
PR   progesterone-receptor 
Raf   rapidly accelerated fibrosarcoma 
Ras   rat sarcoma 
RhoA   Ras homolog gene family, member A 
ROCK   Rho-associated protein kinase 
rhuPIBF  recombinant human PIBF 
RPMI   Roswell Park Memorial Institute 
SDS   sodium dodecyl sulphate 
SH2   src-homology 2 
SOCS   suppressor of cytokine signaling 
STAT   signal transducer and activator of transcription 
TCF   T-cell factor 
TGF   tumor growth factor 
Th1/2   T-helper 1/2 
TIMP   tissue inhibitor of metalloproteinases 
VEGF   vascular endothelial growth factor 
Wnt   Wingless and Int 
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II. INTRODUCTION 
 
1. General features of trophoblast and tumor invasion 
 
Trophoblast and tumor cells share several features [1-4] (Table 1.). Both cell types 
have lost the capacity of contact inhibition and express telomerase activity ensuring high 
proliferation rate. Both tumor and trophoblast cells possess migratory and invasive 
properties and acquire angiogenic potential; moreover, there is an analogy in the 
mechanism of invasion (i.e. adhesion molecules, proteases, matrix metalloproteinases, 
autocrine and paracrine regulation etc.). Finally, both trophoblast and tumor cells are 
capable to suppress the immune system e.g. by expressing non-classical HLA molecules [5-
12], Th2-type cytokines [13-16], immunosuppressive factors [16-18], by inducing 
regulatory T cells [19-28] or by other mechanisms [29-31]. 
 
TABLE 1. Similarities and differences between trophoblast and tumor cells 
TROPHOBLAST TUMOR 
Common features 
Telomerase activity 
High proliferation rate 
Loss of contact inhibition 
Migratory and invasive properties 
Similarities in the mechanism of invasion 
Extensive vascularization 
Ability to suppress the immune system 
Distinctions 
Cell differentiation 
Well differentiated 
Undifferentiated, 
transformed, immortal cells 
with altered morphological 
features 
Invasion 
Physiological process Pathological process 
Regulation of invasion 
Strictly regulated in time 
and space 
Uncontrolled invasion, 
metastatic capacity 
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The major differences between trophoblast and tumor cells reside in cell 
differentiation and spatio-temporal regulation of invasion. 
Trophoblast cells remain well-differentiated during their lifespan; in contrast, 
malignancies consist of undifferentiated, transformed, immortal cells that have lost their 
original morphological features. Furthermore, tumor invasion is a pathological process, 
characterized by uncontrolled invasive behavior and unlimited metastatic capacity, while 
trophoblast invasion is a physiological event that is rigorously regulated, restricted in time 
to the first trimester of pregnancy and localized in space to the endometrium and the 
proximal third of the myometrium. The slightest disturbances of the fine tuning of 
trophoblast invasion may manifest in pathological pregnancies [32-37] (Table 2.). 
 
 
TABLE 2.Clincal consequences of aberrant trophoblast invasion 
REDUCED TROPHOBLAST INVASION 
Early pregnancy loss 
Pre-eclampsia 
Intrauterine growth retardation 
INCREASED TROPHOBLAST INVASION 
Abnormally deep attachment of the placenta 
Placenta accreta 
Placenta increta 
Placenta percreta 
Gestational trophoblastic tumors 
Partial / Complete hydatidiform mole 
Invasive mole 
Choriocarcinoma 
Placental site trophoblastic tumor 
Epithelioid trophoblastic tumor 
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2. Invasive differentiation of trophoblast cells 
 
Trophoblast progenitor cells residing at the basement membrane of placental villi 
(Fig.1.) give rise to distinct epithelial cell types. 
 
 
FIGURE 1. Trophoblast differentiation at the maternal-fetal interface. CT: cell column; A: 
spiral arteries; T: interstitial trophoblast cells; F: fibrinoid; E: endovascular trophoblast 
cells; GC: placental bed giant cells. [38] 
 
 
Fusion of cytotrophoblasts generates the multinucleated syncytium which is mainly 
responsible for protein transport and hormone (progesterone, hCG, hPL) production. 
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Cytotrophoblasts of anchoring villi acquire a transiently invasive phenotype and invade the 
decidualized endometrium while the cytotrophoblasts of floating villi (in the extravillous 
space surrounded by maternal blood) remain attached to the villous basement membrane. 
The inner layer of villous cytotrophoblast grows out at focal points to form cell 
columns. These are prominent at the anchoring villi, where attachment to the maternal 
decidua occurs. At the fetal–maternal boundary, the columns form a partially continuous 
shell. From this shell, extravillous trophoblast cells enter the decidua as interstitial 
trophoblast to encircle and destroy the arterial media, which is replaced by fibrinoid 
material. These cells interact with different maternal cell types including decidual cells, 
leukocytes and endothelial cells. Then, endovascular trophoblast cells move down the 
arteries in a retrograde manner to replace the maternal endothelial lining [38-39]. 
A new subset of extravillous trophoblast cells, the endoglandular trophoblast [40], 
breaks through the basement membrane of uterine glands to open their lumen towards the 
intervillous space. This might enable histiotrophic nutrition of the embryo during the first 
trimester of pregnancy prior to onset of the maternal blood flow. 
The trophoblast cells move as far as the inner myometrium, where they fuse to 
become placental-bed giant cells. 
 
 
3. Common regulators of trophoblast and tumor invasion 
 
Several enzymes, hormones, cytokines, growth factors and extracellular matrix 
glycoproteins have been reported to play a role in both trophoblast and tumor invasion. Few 
selected molecules are addressed below. 
 
3.1 Matrix metalloproteinases 
 
Invasion of surrounding tissues is mediated by a set of proteolytic enzymes, among 
others, matrix metalloproteinases (MMPs). MMPs are zinc-dependent endopeptidases with 
the capacity of degrading extracellular matrix components. In humans, there are 23 MMPs 
and their expression is transcriptionally controlled by inflammatory cytokines, growth 
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factors, hormones, cell-cell and cell-matrix interactions [41-43]. MMP activity is also 
regulated by activation of the precursor zymogens (most MMPs are secreted as inactive 
pro-enzymes) and inhibition by the endogenous tissue inhibitors of metalloproteinases 
(TIMP1,-2,-3,-4). TIMPs bind to the highly conserved zinc-binding site of active MMPs.  
The involvement of MMP-9 and MMP-2 – also known as gelatinases – in tumor cell 
migration and invasion as well as in embryo implantation is well documented. Gelatinases 
are capable to cleave type IV collagen, the main component of basal membranes [44-50]. 
While MMPs and TIMPs are strictly regulated during trophoblast invasion, tumor invasion 
and metastases occur as a result of an imbalance between MMPs and TIMPs [51]. 
 
3.2 Hormones 
 
Progesterone is one of the hormones to control trophoblast invasiveness by reducing 
the secretion of MMP-9 by trophoblasts [48-50]. A set of progesterone-induced genes (p53, 
Indian Hedgehog, BMP-2, galectin-1 etc. [52-58]) also possesses a vital role in 
implantation and decidualization.  
Another molecule that has been implicated in control of trophoblast invasiveness is 
leptin; a 16-kDa peptide hormone secreted by adipose tissue, that participates in the 
regulation of energy homeostasis [59]. Leptin is synthesized by the human placenta [60] 
and its receptors are expressed in the trophoblast and endometrium during pregnancy [61]. 
Human chorionic gonadotropin (hCG) induces leptin expression in trophoblast cells 
probably involving the MAPK signal transduction pathway [62-63]. Leptin also promotes 
the expression of MMP-2 and MMP-9 in cultured human cytotrophoblast cells [64]. Leptin 
inhibits the secretion of progesterone by cytotrophoblast. Abnormal leptin levels in 
preeclampsia are associated with reduced trophoblast invasion. Overexpression of leptin-
receptor was found in ovarian cancer and leptin promotes resistance to apoptosis in lung 
carcinoma. 
 
13 
 
3.3 Growth factors and cytokines 
 
Growth factors and their receptors which play a central role in proliferation show a 
similar expression pattern in trophoblasts and malignant tumors. 
Epidermal growth factor (EGF)-receptors are present in villous cytotrophoblast 
cells, syncytiotrophoblast and decidual cells. The ligands for EGF-receptor - EGF, TGF-α 
and amphiregulin - have been shown to enhance extravillous trophoblast proliferation. EGF 
has been demonstrated in uterine epithelial cells and decidual cells, as well as in cyto- and 
syncytiotrophoblast of the chorionic villi. Tumor growth factor α (TGF-α) has been 
detected in decidual cells and nearly all trophoblast subpopulations. Amphiregulin has been 
demonstrated in syncytiotrophoblast cells of the early placenta. EGF regulates early 
placental growth and function in an autocrine manner. Furthermore, the TGF-α-EGFR 
autocrine loop has been implicated in the uncontrolled proliferation of malignant 
trophoblast cells [65-66]. 
EGF-like growth factors – among others heparin-binding EGF-like growth factor 
(HB-EGF) - are expressed throughout gestation in villous and EVT populations of the 
human placenta. Disruption of the EGF signaling network in human first trimester 
cytotrophoblast cell lines reduced, while supplementation with these growth factors 
increased trophoblast invasiveness [67-68]. 
During tumor growth, angiogenesis is initiated by basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF), which signal nearby vessels to 
send out new branches [69-70]. VEGF is a potent angiogenic factor which plays a role in 
the vascularization process and promotes invasive trophoblast proliferation during embryo 
implantation. Invading extravillous cytotrophoblast cells express the VEGF receptor [71]. 
VEGFR can also be bound by the trophoblast-derived placental growth factor (PlGF); a 
member of the VEGF family of angiogenic factors, to affect cell proliferation, invasion 
and/or other metabolic activities in an autocrine manner. 
Interleukin-6 (IL-6) modulates the expression of genes involved in cell cycle 
progression, apoptosis and angiogenesis. IL-6 has been implicated in the pathogenesis of 
several types of tumors including lymphoma, gastric carcinoma, prostate cancer, ovarian 
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cancer and multiple myeloma. Trophoblast also expresses IL-6 as well as IL-6R and its 
associated signal transducer gp130 [72]. 
 
 
4. Signaling cascades mediating proliferation, migration and invasion 
 
Extracellular stimuli initiate signal transduction that controls proliferation, 
differentiation, migration and apoptosis through the mitogen-activated protein kinases 
(MAPKs), focal adhesion kinase (FAK), the phosphoinositide 3-kinase (PI3K) - Akt 
pathway, Signal Transducers and Activators of Transcription (STATs) (Fig.2.) or the Wnt 
pathway (Fig.3.). 
 
4.1 Mitogen-activated protein kinase (MAPK) cascades 
 
 Upon ligand binding to receptor tyrosine kinases or G-protein coupled receptors, a 
highly complex network of protein kinases and small GTPases (e.g. Ras) regulates the 
activity of MAPKs through sequential phosphorylations at critical Ser, Thr and Tyr 
residues. Proteins of the MAPK-kinase-kinase (MAPKKK) family such as Raf 
phosphorylate MAPK-kinases (MAPKKs) including MEKs. The MAPKKs then activate 
the four major families of MAPKs including the ERK family. 
ERKs have been shown to play an important role in growth-factor-dependent 
regulation of trophoblast growth and migration [73]. In the placenta, the expression of 
ERK1 and ERK2 was detected in villous cytotrophoblasts, but their active phosphorylated 
forms were only present until the 12th week of gestation, suggesting a predominant role 
during early pregnancy [74]. Chorionic gonadotropin uses ERK pathway to facilitate 
trophoblast invasion and migration due to inducing MMP-2 expression [75]. EGF-induced 
trophoblast migration also requires ERK signaling cascades [76]. MAPK signaling is 
dysregulated in various malignancies [77-79]. 
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4.2 PI3K/Akt pathway 
 
The Akt cascade is activated by receptor tyrosine kinases, integrins, cytokine 
receptors, G-protein coupled receptors and other stimuli that induce the phosphoinositide 3-
kinase (PI3K) mediated transition of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5 triphosphate (PIP3). Elevated PIP3 recruits and activates the 
protein-serine/threonine kinase Akt at the membrane. Once activated, Akt phosphorylates a 
number of target proteins, including direct regulators of cell growth, proliferation, survival, 
and migration, transcription factors and other protein kinases. 
Akt regulates invasive differentiation of trophoblast cells [73]. In many tumors, Akt 
promotes metastasis [80-82]. EGF is a potent activator of PI3K-Akt and Akt-dependent 
migration of trophoblastic HTR-8/SVneo cells [76]. PI3K-Akt is also required for hCG- 
and EGF-dependent expression of MMP-2 and MMP-9 in trophoblasts [75-76], Since these 
enzymes are also targets of ERK signaling, PI3K-Akt and MAPK signaling may have 
synergistic effects on protease expression and trophoblast invasion. 
 
4.3 JAK/STAT pathway 
 
Phosphorylation, dimerization and nuclear translocation of STAT transcriptional 
factors are achieved upon growth factor or cytokine-dependent activation of receptor-
associated Janus kinases (JAKs). Cytokine binding induces receptor dimerization and 
activates associated JAK proteins which phosphorylate themselves and the receptor. 
Phosphorylated sites on both receptor and JAKs serve as docking sites for the SH2-
containing STAT proteins. Receptor-bound STATs phosphorylated by JAKs dimerize and 
translocate to the nucleus to regulate target gene transcription. 
The role of STAT3 in trophoblast [83-85] as well as in tumor invasion and 
metastasis has been regularly affirmed [86-88]. Among others, IL-6 and leptin were shown 
to increase STAT3 activity in cytotrophoblast cells. Dysregulation of JAK/STAT pathway 
leads to increased angiogenesis, enhanced survival of tumors and immunosuppression. 
Malignant choriocarcinoma was found to possess high level of STAT3 activity [84]. Xie et 
al reported that STAT3 upregulates the transcription of MMP-2 through direct interaction 
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with the MMP-2 promoter [89], in addition, transfection of human melanoma cells with a 
dominant-negative STAT3 suppressed brain metastasis in animal models [90]. 
 
 
 
FIGURE 2. Signaling pathways in control of proliferation, differentiation, cell growth, 
apoptosis, migration and invasion 
 
 
4.4 Wnt signaling 
 
The Wnt proteins belong to a family of secreted morphogenes that play a key role in 
embryonic development and tumorigenesis. In the canonical pathway, Wnt ligands bind to 
the heterodimeric low-density lipoprotein receptor-related protein (LRP) and Frizzled 
(Fzd). Signaling from LRP/Fzd leads to activation of a cytoplasmic protein called 
Dishevelled (Dvl) and inhibition of the complex composed of axin, adenomatous polyposis 
coli (APC) and glycogen synthase kinase 3β (GSK-3β). In the absence of Wnt ligands, 
active GSK-3β phosphorylates β-catenin, leading to its ubiquitination and degradation. Wnt 
signaling results in increased β-catenin levels. β-catenin acts as a direct regulator of gene 
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expression by forming a complex with members of the T-cell factor (TCF)/lymphoid 
enhancer binding factor (LEF) family of transcription factors. To control canonical Wnt 
signaling, secreted Dickkopf (Dkk) members inhibit the pathway upon interaction with 
LRP-5/6. 
Several Wnts activate β-catenin independent signaling pathways (non-canonical 
Wnt signaling pathways), known as the planar cell polarity pathway and Wnt/calcium 
pathway. Furthermore, non-canonical Wnts can antagonise the functions of canonical Wnts. 
 
 
 
FIGURE 3. Wnt signaling. Canonical Wnt signaling pathway (left panel): In the presence 
of the Wnt molecule, Dvl inhibits GSK-3β and β-catenin translocates to the nucleus and 
induces the transcription of the target genes. Two major non-canonical Wnt signaling 
pathways, the planar cell polarity and Wnt/calcium pathways are shown on the right panel.  
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Fourteen out of 19 Wnt ligands and 8 out of 10 Fzd receptors were detectable in the 
human placenta, indicating that Wnt signaling might be involved in trophoblast 
differentiation. Wnt-dependent transcription factors were found to be predominantly 
expressed in p57/Kip2-positive, invasive trophoblasts [91]. Moreover, Wnt-3a promoted 
trophoblast proliferation, migration and invasion through both canonical and non-canonical 
signaling, the latter was manifested through activation of Akt, which is also a well-known 
target of the invasion-promoting factors: EGF and IGF-II in trophoblasts. In complete 
mole, the majority of extravillous trophoblasts were shown to contain nuclear β-catenin, 
suggesting that aberrant Wnt signaling could be involved in excessive trophoblast invasion. 
 
4.5 Other pathways 
 
Focal adhesion kinase (FAK) is a widely expressed non-receptor protein tyrosine 
kinase that has a growth/migration-promoting role. The activation of FAK is achieved by 
phosphorylation at different amino acid residues, in particular by phosphorylation at Tyr-
397. FAK activity was shown to be associated with tumor progression of cancer cells 
towards a malignant phenotype [66, 92]. 
FAK also has an impact on activities of Rho proteins, a family (RhoA, Racl, Cdc 
42) of particular GTPases regulating diverse biological processes such as cell cycle, cell–
cell/focal adhesions, polarization and cell migration [66, 93]. The downstream effectors of 
Rho include p21-activated kinase (PAK), which cross-talks to the MAPK pathway by 
modulating Raf and Rho-associated, coiledcoil containing protein kinase (ROCK). The 
functionality of the RhoA–ROCK signaling cascade has also been suggested during 
trophoblast migration. 
 
 
5. Progesterone-dependent immunomodulation: pregnancy-protective effect 
of PIBF 
 
During pregnancy, the immunological effects of progesterone are mediated by the 
progesterone-induced blocking factor (PIBF). Following recognition of fetal antigens, 
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maternal lymphocytes get activated and express progesterone receptors [94-98]. In the 
presence of progesterone these cells produce PIBF [99-100]. PIBF is also widely expressed 
in the decidua, in the placenta as well as in the amnion. [101]. 
The gene coding for PIBF is situated on chromosome 13 between loci 13q21 and 
13q22 in the neighbourhood of the homeobox gene, KLF-5 and KIAA1008 [102]. The 
PIBF1 gene, containing 18 exons, is 2765 bp in length with an open reading frame of 2271 
bp and encodes a 90-kDa protein consisting of 757 amino acids (Fig.4.). 
 
 
 
FIGURE 4. The structure of PIBF1 gene. (C: Chromosome, ORF: open reading frame, 
bZIP: basic-leucine zipper, NLS: nuclear localization signal, E: exon). NLS: on exon-7 and 
exon-13; LeuZip: on exon-8 and exon-15/16; bZip: on exon-14. 
 
 
In recurrent miscarriage and in women showing clinical symptoms of threatened 
preterm pregnancy termination, the percentage of PIBF positive peripheral lymphocytes is 
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significantly lower than in healthy pregnant women [99, 103-104], suggesting that PIBF 
production is related to the outcome of pregnancy [105]. This concept is further supported 
by the finding that neutralizing endogenous PIBF in pregnant mice results in fetal 
resorptions [106]. 
PIBF supports the pregnancy via inhibiting NK activity [106-108], facilitating the 
production of asymmetric antibodies [109] and altering the Th1/Th2 cytokine balance [110-
112]. (Fig.5.) 
 
 
 
FIGURE 5. PIBF activates the Jak1/STAT6 and PKC/Ca++ - pathways which results in 
Th2-type cytokine production. PIBF induces SOCS3 which inhibits STAT4 
phosphorylation, thus inhibits Th1 response through binding to the IL-12R. PIBF has the 
capacity to alter the arachidonic acid metabolism, and to inhibit NK activity. 
 
 
Successful pregnancy is characterized by Th2 dominant cytokine pattern [113-114]. 
Activated lymphocytes cultured in the presence of PIBF produce increased amounts of the 
Th2-type cytokines IL-3, IL-4 and IL-10 [112], and decrease the production of the Th-l 
cytokine IL-12. Based on our data, PIBF induces Th2-biased cytokine production via the 
Jak1/STAT6 [115] and PKC/Ca++ - pathways [116]. 
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Jak1/STAT6 pathway 
 
PIBF induces the phosphorylation and nuclear translocation of STAT6 
transcriptional factors and inhibits the phosphorylation of STAT4 molecules, which results 
in Th2 dominant cytokine balance. 
Activation of the STAT6 pathway was known to be initiated through the IL-4 
receptor uniquely, but previously we have demonstarted a novel type of IL-4R composed of 
the alpha chain of IL-4 receptor and the PIBF-receptor. PIBF does not bind to IL-4Rα but 
to its own receptor [115]. The STAT6 activating effect of PIBF can be abolished by 
blocking of IL4-R subunit. In addition, PIBF activates JAK1 (associated with IL-4Rα, 
suggesting that IL-4R is involved in PIBF signaling. PIBF does not phosphorylate Jak3 
(associated with the common γ chain) and anti-IL-13Rα treatment has no effect on PIBF 
induced STAT6 activation, suggesting that the common γ-chain and the IL-13R subunits 
of IL-4 family do not take part in the signaling process of PIBF. 
 
PKC/Ca2+ pathway 
 
PIBF also affects the PKC/Ca2+ pathway which is involved in the regulation of Th1 
and Th2 immune responses. High levels of PKC activity combined with low calcium 
signals favour Th2 development, while predominance of calcium signaling with low PKC 
activity favours Th1 development [116]. 
In peripheral lymphocytes, PIBF induces the phosphorylation of PKCζ and PKCΘ 
isoforms without affecting the intracellular Ca2+ level supporting a Th2-type cytokine 
pattern. 
 
SOCS1 and SOCS3 
 
Suppressor of cytokine signaling (SOCS) proteins negatively regulate the signal 
transduction of several cytokines [117]. PIBF-induced SOCS-3, through binding to the IL-
12R, inhibits STAT4 phosphorylation and Th1 responses in peripheral lymphocytes[115]. 
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6. A possible role for PIBF in tumor progression and in regulation of 
invasion 
 
Recent literature shows that PIBF is not only expressed during pregnancy, but it is 
also produced by undifferentiated, proliferating cells and a set of malignant tumors. 
Lachmann et al. reported that various breast tumors overexpress PIBF compared to normal 
breast tissues both at the mRNA and protein levels. Moreover, MCF-7 mammary 
carcinoma cells produce PIBF in the absence of progesterone [118]. 
In vitro data showed that human leukemia cell lines express mRNA for PIBF, and 
some of these cell lines also express the PIBF protein. In these cell lines PIBF production 
was up regulated by progesterone and down regulated by mifepristone [119]. 
Rozenblum et al. [120] identified the PIBF1 gene on the chromosomal region 
13q21-q22 which has been implicated as a common site for somatic deletions in a variety 
of malignant tumors. 
Lachmann et al. [118] demonstrated that the full-length form of PIBF is associated 
with the centrosome. A number of proteins shown to be involved in tumorigenesis are 
associated with the centrosome. The most prominent example is the best-characterized 
breast cancer susceptibility gene BRCA1 that is linked to the development of breast and 
ovarian cancers. Recent genetic studies indicated PIBF among the candidate genes for 
breast cancer predisposition and cancer progression. 
The distribution of PIBF within the first trimester decidua coincides with sites of 
trophoblast invasion showing the strongest PIBF positivity at the extravillous trophoblast 
[101]. Check et al reported that early detection of PIBF may be related to premature 
trophoblast invasion possibly into an endometrium not yet prepared for the trophoblast and 
might lead to early immune rejection of the fetus [121]. 
Based on these data, the aim of my research project was to uncover a possible role 
of PIBF in regulation of invasion. 
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III. AIMS OF THE PROJECT 
 
 
This work aims to investigate the involvement of Progesterone-Induced Blocking 
Factor (PIBF) in the regulation of invasion; and to identify the signaling networks via 
which it affects the invasive behavior of tumor cells, contributes to the success of 
implantation during pregnancy by regulating trophoblast invasion and participates in the 
pathogenesis of trophoblastic diseases. 
 
Specific aims: 
 
I. To confirm the involvement of PIBF in trophoblast and tumor invasion 
 To analyse PIBF expression in trophoblast cells with different degrees of 
invasiveness; 
 To investigate the effect of PIBF knock down on trophoblast and tumor 
invasion; 
 To determine, whether PIBF has a role in matrix remodelling. 
 
II. To analyse PIBF-induced invasion-related signaling pathways 
 To characterize the PIBF-receptor; 
 To uncover PIBF-induced signaling pathways involved in invasion; 
 To investigate the subcellular localization of PIBF; 
 To identify the function of nuclear PIBF. 
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IV. MATERIALS AND METHODS 
 
 
1. Separation of lymphocytes 
 
Peripheral blood mononuclear cells (PBMC) were separated from heparinized 
venous blood of healthy, non-pregnant volunteers by Ficoll-Hypaque discontinuous density 
gradient centrifugation. 
 
2. Cell lines 
 
The immortalized human first-trimester extravillous trophoblast cell line 
HTR8/SVneo was a kind gift from Charles H. Graham (Queen’s University, Kingston, 
Ontario, Canada). HT-1080 fibrosarcoma cell line was purchased from ATCC. 
Cell lines were kept at 37°C in a humidified atmosphere of 5% CO2 under the 
following conditions: HT-1080 cell line was cultured in DMEM (Sigma-Aldrich) 
supplemented with L-Glutamine, MEM Non Essential Amino Acid Solution (Sigma-
Aldrich), 10% heat inactivated fetal bovine serum (Gibco), penicillin and streptomycin 
(100 IU/ml and 100 µg/ml, respectively); HTR-8/SVneo cells were cultured in RPMI 
(Gibco) supplemented with 10% heat inactivated fetal bovine serum, 100 IU/ml penicillin 
and 100 µg/ml streptomycin. 
 
3. Recombinant human PIBF and PIBF antibodies 
 
The recombinant human PIBF was produced in our laboratory according to a 
method described earlier [102]. Briefly: Based on the previously described structure of 
PIBF1 cDNA, a 1255 bp length segment of the N-terminal PIBF was ligated into a 
gluthatione S-transferase fusion vector (pGex-4T1), and transformed into E. coli BL21pLys 
host strain. PIBF was purified on a Glutathione-Sepharose 4B affinity column. 
Fluorescein-isotiocyanate conjugated N-terminal recombinant human PIBF (PIBF-
FITC) was also generated. 
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Polyclonal anti-PIBF antibodies and anti-exon17 were generated in our laboratory 
by immunizing rabbits with the 48-kDa N-terminal recombinant human PIBF or exon-17. 
The antibody titers were determined by ELISA. IgG was affinity purified on protein A 
columns. 
Monoclonal anti-PIBF antibodies were generated in the Department of Immunology 
and Biotechnology, University of Pecs by immunizing mice with the 48-kDa N-terminal 
recombinant human PIBF. 
 
4. Treatment of cells 
 
After 4 h starving lymphocytes were incubated at 37°C for 20 minutes with the 
following:  
 E. coli lysate (that had undergone the same purification procedure as the 
recombinant human PIBF) in a concentration of 200 ng to 5x107 cells, as a control 
to exclude the effect of LPS contamination on cytokine production; 
 48-kDa N-terminal recombinant human PIBF at a concentration of 20, 100, 200 or 
500 ng to 5x107 cells; 
 recombinant human IL-4 (RD Systems Europe Ltd) at a concentration of 200 ng 
to 5x107 cells. 
After 16 h starving HTR8/SVneo and HT-1080 cells were incubated at 37°C for 5, 
20 minutes, 1, 6 or 24 hours with the following:  
 RPMI medium 1640 or DMEM as a control; 
 E. coli lysate at a concentration of 100 ng to 6x105 cells; 
 48-kDa N-terminal recombinant human PIBF at a concentration of 100 ng to 6x105 
cells. 
 
5. Placental sections and immunohistology 
 
Paraffin-embedded sections from hydatiform moles and choriocarcinomas were 
obtained from archives at the University of the Philippines (Manila, Philippines), the 
Gynaecology and Oncology Department of the Jagiellonian University (Krakow, Poland), 
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the Gynaecology and Oncology Department of the Lukaszczyk Oncological Center 
(Bydgoszcz, Poland) and the Clinical Gynaecology and Obstetrics Department (Rzeszow, 
Poland). 
Five micrometer tissue sections of the formalin-fixed, paraffin-embedded blocks 
were mounted on gelatine-coated (Sigma-Alrich) slides. Sections were deparaffinized and 
rehydrated through graded alcohols to water. Endogenous peroxidase activity was blocked 
with 1% H2O2 in methanol. Antigen retrieval was carried out with 10 mM citrate buffer in a 
microwave oven. After pre-blocking with 1% BSA (Sigma-Aldrich) the sections were 
reacted with polyclonal anti-PIBF (diluted 1:100), 1:50 diluted polyclonal anti-leptin 
(Abcam) or 1:100 diluted monoclonal anti-leptin receptor antibodies (LifeSpan 
Biosciences). 
Peroxidase-conjugated secondary antibodies (diluted 1:100) were applied 
(DakoCytomation) followed by incubation with AEC (3-amino-9-ethylcarbazole) substrate 
(Beckton Dickinson). The slides were counterstained with haematoxylin and coverslipped. 
Images were visualized with a Nikon FXA microscope. Images were taken with a digital 
camera (Nikon) using SPOT Advanced computer software program (SPOT Imaging 
Solutions). 
 
6. Co-capping of IL-4R and PIBF receptor 
 
One million lymphocytes were incubated with 5 µg of recombinant human PIBF-
FITC for 30 min at 4oC. Then cells were washed twice in PBS containing 1% FCS and 
incubated with 5 µg of mouse monoclonal anti-human IL-4Rα or 10 µl of PE-labelled 
mouse anti-human CD45-RA antibody for 45 minutes at 37°. Cells were washed twice and 
incubated with 20 µl of PE-labelled rat anti-mouse IgG2A+B or PE-labelled rat anti-mouse 
IgG1 for 20 minutes at 37°C. Then cells (1x105) were plated on poly-L-lysine coated slides 
and incubated at 37 oC for further 10 minutes, then washed twice in PBS containing 1% 
FCS and fixed with freshly prepared 3% paraformaldehyde in PBS for 10 minutes at room 
temperature. After washing the slides were mounted with DABCO (Sigma Aldich). 
To control the specificity of the capping formation, we performed all steps at 4C. 
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Ligand-induced capping was also investigated. First, one million cells were 
incubated with 5 µg of FITC-conjugated 48-kDa rhuPIBF for 20 min at 37oC. One hundred 
thousand cells were plated on poly-L-lysine coated slides and incubated at 37oC for further 
10 minutes then washed twice in PBS containing 1% FCS and fixed with freshly prepared 
3% paraformaldehyde in PBS for 10 minutes at room temperature. Cells were washed twice 
and incubated with 2 µl of PE-labelled mouse monoclonal anti-human IL-4Rα for 45 
minutes at room temperature. After washing the slides were mounted with DABCO. 
Microscopic analysis was performed with a BioRad confocal microscope with 100x 
objective, using laser excitation at 473 nm and filters 580+/-16 nm for phycoerythrin and 
522+/-17.5 nm for FITC. Images were analysed using the Adobe Photoshop 7.0 program.  
 
7. Digestion of lymphocytes with phosphatidylinositol-specific 
phospholipase C (PI-PLC)  
 
Five million PHA-pretreated PBMC was incubated with 2.5 units of 
phosphatidylinositol-specific phospholipase C (Sigma-Aldrich) for cleaving of the GPI-
anchor in 1 ml of RPMI for 20 min at 37°C.  
 
8. Depletion of plasma membrane cholesterol by methyl-β-cyclodextrin 
(MβCD) 
 
To determine the effect of disrupting lipid rafts on PIBF-induced STAT6-activation, 
five million PHA-pretreated PBMC was incubated with 10mM of methyl- β-cyclodextrin 
(Sigma-Aldrich) in 1 ml of RPMI for 20 minutes at 37C. The effect of MβCD on cell 
viability was controlled by Trypan blue. This concentration of MCD depletes cholesterol 
but does not kill the cells. 
 
9. Flow cytometry 
 
 For the detection of PIBF-receptor positive cells, lymphocytes, HTR-8/SVneo and 
HT-1080 cells were washed with PBS and one million cells were labeled with 1 µg FITC-
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conjugated recombinant 48-kDa PIBF in 100 µl PBS supplemented with 1% FCS and 0.1% 
azide for 20 minutes at 4°C. After washing with PBS for 5 min, 2000 rpm at 4°C, cells 
were fixed with 2% paraformaldehyde. 
 For Annexin V staining, HTR-8/SVneo and HT-1080 cells were washed with PBS 
twice and one million cells were resuspended in 1X Binding Buffer (BD Biosciences). 
Then 1x105 cells were incubated with 5 µl Annexin V-FITC for 15 min at room 
temperature. Finally, 200 µl of 1x Binding Buffer was added. 
Labeled cells were analysed with a FACSCalibur flow cytometer (Beckton 
Dickinson Immunocytometry Systems) equipped with the CellQuest software program 
(Becton Dickinson) for data acquisition and analysis. 
 
10. Silencing of PIBF, IL-4Rα or HB-EGF by siRNA 
 
Oligonucleotides were pre-designed to interfere with IL-4Rα, PIBF or HB-EGF 
mRNA (Ambion). Cells were washed with OptiMEM (Invitrogen Life Technologies). 
Specific oligonucleotides or scrambled siRNA (control) were incubated for 20 min at room 
temperature with Oligofectamine (Invitrogen Life Technologies). This mixture was added 
dropwise to the cells. After 4 h incubation at 37°C, DMEM containing 30% FCS and L-
glutamine was added to cultures and Western blot analyses for IL-4Rα, PIBF or HB-EGF 
expression were performed after 24, 48 or 72 hours subsequent to siRNA transfection. 
 
11. Western blotting 
 
After washing, treated cells were lysed in three volumes of high salt buffer 
containing 20 mM HEPES (pH 7.9), 20 mM NaF, 1mM Na3VO4, 1 mM Na4P2O7, 1mM 
EDTA, 1mM EGTA, 5mM DTT, 0.5mM PMSF, aprotinin (0.01g/mL), leupeptin 
(0.025g/mL), 400 mM NaCl and 20% glycerol at 4ºC. Samples were frozen and thawed 
three times, then incubated on ice for 20 minutes. After centrifugation at 15000 rpm at 4C 
for 30 minutes the supernatants were collected and its protein content was determined. 
Following SDS-PAGE (40 min, 120 V) proteins were transferred to nitrocellulose 
using a Hybond ECL membrane (Amersham Biosciences) at 54 mA overnight. Membranes 
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were blocked with TBS-Tween (pH 7.4) containing 5% non-fat dried milk for an hour and 
incubated with rabbit polyclonal phospho-specific (Tyr-641) anti-human STAT6, rabbit 
polyclonal anti-human STAT6, rabbit polyclonal phospho-specific (Tyr-980) anti-human 
Jak3, rabbit polyclonal phospho-specific (Ser473) anti-human Akt antibodies (all from 
Santa Cruz Biotechnology Inc.) in TBS-Tween with 3% non-fat dried milk for an hour, 
mouse anti-β-catenin (Santa Cruz Biotechnology Inc.), rabbit anti-human phospho-STAT3 
(Tyr705), rabbit anti-human phospho-STAT3 (Ser727), rabbit anti-human phospho-p44/42 
MAPK (Thr202/Tyr204), rabbit anti-human Wnt5a, rabbit anti-human phospho-PKCζ/λ, 
rabbit anti-human phospho-PKCδ (all from Cell Signaling Technology Inc.), mouse anti-
leptin-receptor (LifeSpan Biosciences) antibodies in TBS-Tween with 5% BSA overnight 
at 4°C or as control with rabbit anti-human -actin (Sigma) in TBS-Tween with 3% non-fat 
dried milk for an hour. After washing (3x10min in TBS-Tween) bound antibodies were 
detected with 1:2000 diluted horseradish peroxidase-conjugated goat anti-rabbit IgG or 
goat anti-mouse IgG (1 hour at room temperature) followed by development with ECL 
reagents (Perkin Elmer Life Sciences). Semi-quantification of the bands were performed by 
densitometry using ImageJ software. 
 
12. Invasion assay 
 
OrisTM Cell Invasion and Detection Assay (Platypus Technologies) was used to 
detect invasion in PIBF-silenced cells (Fig.6.). Basement membrane extract at the 
concentration of 3 mg/ml was applied on collagen-coated 96-well plates and the latter 
populated with OrisTM Cell Seeding Stoppers which restrict cell seeding to the outer 
annular regions of the wells. Then wells were seeded with 75000 cells with or without 
siRNA (final cc. 25 nM). The stoppers were removed after 24 hours and OrisTM basement 
membrane extract at the concentration of 12 mg/ml with 15% FBS was overlayed on the 
cells. Removal of the stoppers reveals a 2 mm diameter unseeded region in the center of 
each well, i.e., the detection zone, into which the seeded cells may then invade. The plate 
was incubated in a humidified chamber for 72 hours to permit cell invasion. 
After 72 hours, supernatants were collected for substrate zymography then cells 
were labelled with Calcein AM. After applying the mask that blocks the outer seeding 
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region from view, images were captured using multi area scan by an Olympus Fluoview 
FV-1000 confocal microscope (OBJ: 20x, NA:0.45; excitation: 488 nm, detection: 500-600 
nm). 
 
 
 
FIGURE 6. The principle of OrisTM Invasion and Detection Assay. 
 
 
13. Substrate zymography 
 
Cell-conditioned media (20 μl from the OrisTM plates) were subjected to 
electrophoresis under nonreducing conditions in a 7.5% acrylamide gel containing 1 mg/ml 
(0.01%) gelatin to detect MMP-2 and MMP-9 secretion. After electrophoresis, gels were 
washed twice in 2.5% Triton X-100 for renaturation and then incubated at room 
temperature then at 37 °C overnight in buffer containing 50 mM Tris–HCl, 5 mM CaCl2 
(pH 7). Thereafter, gels were stained with 0.5% (wt/vol) Coomassie Blue G-250 for 40 min 
and destained in 50% (vol/vol) methanol/10% (vol/vol) acetic acid until lysed bands were 
visible. Semi-quantification of the bands corresponding to 92-kDa gelatinase (MMP-9) and 
72-kDa gelatinase (MMP-2) was performed by densitometry using ImageJ. 
 
14. Confocal microscopy 
 
Twenty thousand cells of HTR-8/SVneo or HT-1080 were plated on poly-L-lysine 
coated slides and incubated at 37oC for 20 minutes, then washed with PBS containing 1% 
FCS. Cells were fixed and permeabilized with acetone for 10 minutes at -20°C. Cells were 
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blocked with PBS containing 1% BSA and 10 mM HEPES for 20 minutes and incubated 
with anti-48kDa PIBF or anti-phospho-PKCδ antibody for one hour at room temperature. 
After washing the slides with PBS containing 1% BSA and 10 mM HEPES three times for 
5 min, cells were incubated with Cy3-conjugated anti-rabbit-Ig for 30 minutes at room 
temperature. After washing nucleus was stained by Hoechst 33258 for 20 minutes at room 
temperature then cells were mounted with DABCO and slides were closed by nail polish. 
Microscopic analysis was performed with an Olympus Fluoview FV-1000 confocal 
microscope with 60x oil immersion objective, using laser excitation at 405 nm and 
detection at 425-475 nm for Hoechst staining and laser excitation at 543 nm and detection 
at 555-655 nm for Cy3 dye. Images were analysed using the Olympus Fluoview 1.7 
software. 
 
15. Immunocytochemistry 
 
Cytocentrifuge-prepared cultured cells of HT-1080 and HTR-8/SVneo were used to 
study PIBF expression. Samples were fixed in acetone at 4 °C for 10 min then washed with 
TBST. Peroxidase blocking reagent was added for 10 min, then rinsed twice with destilled 
water and twice with TBST. Non-specific binding sites were blocked with 1% BSA-TBST 
for 20 min. The primary antibody anti-48kDa PIBF and preimmune rabbit IgG as negative 
control were diluted 1:100 in 0.5% BSA-TBST for 1 h, then incubated with HRPO-
conjugated anti-rabbit IgG for 30 min before addition of DAB chromogenic substrate 
(Dako) for 8 min. Cells were counterstained with Mayer’s hematoxylin. Slides were 
mounted with glycerol gelatin and viewed through a Nikon microscope. 
 
16. Protein arrays 
 
Cells were treated with human recombinant PIBF (100ng/1x107 cells) in RPMI at 
37°C for 20 min. As control, treatment with the lysate of E. coli that had undergone the 
same purification procedure as the recombinant human PIBF was used. Then cells were 
solubilized in lysis buffer (1x107 cells/ml) containing 1% NP-40, 20 mM Tris-HCl (pH 
8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
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and 10 µg/ml pepstatin. Samples were analysed by Proteome Profiler Antibody Array 
(Human Angiogenesis Array Kit, R&D Systems) according to the manufacturer’s 
instructions. Briefly, nitrocellulose membranes bearing capture antibodies in duplicates 
were blocked for one hour at room temperature while samples were diluted (400 µg protein 
content) and mixed with a cocktail of biotinylated detection antibodies. Sample/antibody 
mixtures were incubated with the membranes at 4°C overnight. Following wash, 
Streptavidin-HRP and chemiluminescent detectiom reagents were added sequentially. 
Array data on developed X-ray film were quantitated by ImageJ software. 
 
17. Isolation of nuclear fractions 
 
 2.5x107 HTR-8/SVneo and HT-1080 cells were pelleted and resuspended in 500 µl 
Puffer A (pH 7.2) containing 5 mM Tris-HCl (pH 8.0), 1 mM EGTA, 50 mM EDTA, 
protease and phosphatase inhibitors and incubated for 15 min on ice. After centrifugation at 
800 g for 15 min at 4°C, supernatants were collected and frozen (cytosol fraction) while 
pellets were resuspended in 1 ml Puffer A supplemented with 0.5% Triton X-100 and then 
centrifuged with 800 g for 15 min at 4°C. Pellets were sonicated in 1 ml Buffer A on ice, 
then proteins were precipitated with 170 µl 72% trichloroacetic acid for 10 min on ice. 
After centrifugation at 13200 rpm for 10 min, pellets were resuspended in acetone (-20°C), 
sonicated and kept on ice for 2 min, - these steps were repeated three times. Finally, the 
pellet was resuspended in 1X SDS buffer, sonicated, and kept at 4°C overnight. After 
centrifugation, samples were boiled and subjected to SDS-PAGE and Western blot. 
 
18. Cytometric Bead Arrays 
 
IL-6 concentrations were determined by Cytometric Bead Array (CBA). 
Supernatants of PIBF silenced cells were incubated with labeled capture beads and 
detection reagent for 3 h in the dark at room temperature, and analyzed with flow cytometer 
(FACSCalibur; BD Biosciences) by using the respective CBA Analysis software (BD 
Biosciences). 
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19. Chromatin immunoprecipitation (ChIP) 
 
 1x108 HTR-8/SVneo and HT-1080 cells were grown to confluency then cross-
linked with 1% formaldehyde for 10 min at room temperature. Cells were scraped into cold 
PBS containing protease inhibitors. Cells were pelleted for 10 min at 1500 rpm at 4°C then 
lysed in Cell Lysis Buffer containing 5 mM HEPES (pH 8.0), 85 mM KCl and 0.5% NP-40 
for 10 min on ice. After centrifugation at 4500 rpm for 5 min, pellet was resuspended in 
Nuclei Lysis Buffer (1%SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1) for further 10 min 
on ice. Lysate was sonicated on ice/ethanol bath to shear DNA to lengths between 200 and 
1000 basepairs. Samples were centrifuged for 15 min at 13200 rpm at 4 °C and four 200 µl 
aliquots were diluted 10-fold with ChIP Dilution Buffer (0.01% SDS, 1.1% TritonX-100, 
1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl, protease inhibitors) while one 
50 µl aliquot was frozen for input. After pre-clearing with 50 µl blocked (BSA and salmon-
sperm DNA) Protein-G Agarose beads (Sigma) for 2 hours at 4°C, chromatin was 
incubated with 10 µg monoclonal anti-PIBF antibody or control IgG overnight at 4°C. 
Antibody/protein/DNA complex were isolated by immunoprecipitation with 60 µl of 
blocked Protein-G Agarose beads. After extensive washing, the pellets were treated with 
freshly prepared elution buffer (1% SDS; 0.1 M NaHCO3) and  
 
 the eluted protein/DNA complexes were decrosslinked with 20 µl 5 M NaCl for 6 
hours at 65°C, then eluates were concentrated 4-fold by Amicon® Centricon® 
Centrifugal Filter Devices. 30 µl of eluates were separated on SDS-PAGE and the 
protein content of eluates were analysed by Western blotting; or 
 the eluted protein/DNA complexes, together with the 10-fold diluted inputs were 
treated with 10 µl EDTA (pH 8.0), 20 µl 1 M Tris-HCl (pH 6.5) and 1 µl of 20 
mg/ml Proteinase K for 2 hours at 55°C to digest the protein content, then 20 µl 5 M 
NaCl was added and samples were further incubated overnight at 65°C. DNA was 
recovered by using Qiagen PCR Purification Kit (Qiagen) and used as a template 
for PCR. The PCR primers for the ChIP assay were designed to correspond to the 
promoter regions of Wnt5a, EGF, IL-6 and FGF-1 (Table 3.). 
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TABLE 3. Sequences of PCR primers used in ChIP assays. 
Gene  Chromosome  No.  Product Position Sequence  Tm
IL‐6  Chr.7  # 1  494 bp 22766592‐22767085 5’‐CGCTAGCCTCAATGACGACC‐3’ 58,0
              5’‐GAAGGCAACTGGACCGAAGG‐3’  58,4
      # 2  308 bp 22766304‐22766611 5’‐CATAATCCCAGGCTTGGGGG‐3’ 58,1
            5’‐GGTCGTCATTGAGGCTAGCG‐3’ 58,0
      # 3  238 bp  22765324‐22765561  5’‐CAGAGGACCACCGTCTCTGT‐3’  58,5
               5’‐GCTGAAACCAGACCCTTGCA‐3’  58,1
PlGF  Chr.14     107 bp  75422381‐75422487  5’‐GTCTGGACCTGCCGAGAG‐3’  57,5
               5’‐AGGTTCCCGAGCCGAGTT‐3’  59,0
EGF  Chr.4     290 bp  110833882‐110834171  5’‐AGCGAGTTATCTCCTCTTTGGCAGT‐3’  59,8
              5’‐ACAGAGCAAGGCAAAGGCTTAGAGA‐3’ 60,2
FGF‐1  Chr.5  # 1  186 bp  142067460‐142067645  5’‐ACAGGGTTTCACAACTGGACATAA‐3’  56,5
              5’‐CCAGATTCCCCCCCTCCTA‐3’  58,1
      # 2  166 bp  142066039‐142066204  5’‐GCAGGGATGCCAGATGACA‐3’  57,6
               5’‐TGTGTGAGCCGAATGGACTTC‐3’  57,4
      # 3  177 bp  142064721‐142064897  5’‐TCAGGGTTTTGGTAGGGTGGTA‐3’  57,8
               5’‐GATGTGGGTGTGGATAGTGTATGTG‐3’ 57,1
Wnt5a  Chr.3  # 1  457 bp  55521340‐55521796  5’‐GAGAGGCGCTCCGTTTCCAA‐3’  60,1
              5’‐CTTGTGCGTTTTCAGCGGCA‐3’  59,4
      # 2  246 bp  55502025‐55502270  5’‐GCCACAGTTGGCTGAGGTGA‐3’  60,2
            5’‐TGCAGAATGGAAACCCATGCCT‐3’ 59,6
      # 3  116 bp  55524169‐55524284  5’‐AATAAAGGTTTGTGGTTGGGTA‐3’  52,3
              5’‐AAGGCAGTTCGTGTAGAGGAT‐3’  55,7
      # 4  109 bp  55521321‐55521429  5’‐AAGGTCTTTTGCACAATCACG‐3’  54,0
               5’‐CGCAGGCAACTGTTCCAC‐3’  57,2
      # 5  149 bp  55518933‐55519081  5’‐CCAGCAAATGGGACTCGG‐3’  56,2
               5’‐AAGCGGGAAAGCAACACT‐3’  55,1
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V. RESULTS 
 
 
1. The role of PIBF in invasiveness 
 
 
1.1 Expression of PIBF in normal first trimester trophoblast and trophoblastic 
diseases 
 
Controlled trophoblast invasion is a key process during human placentation and a 
prerequisite of successful pregnancy. 
In case of gestational trophoblastic tumors, trophoblast invasion is increased. 
Hydatidiform mole or molar pregnancy arises when the sperm and egg join but do not 
develop into a fetus, however, the placental elements continue to grow forming a tissue that 
resembles grape-like cysts. Hydatidiform moles may be partial (containing some embryonic 
or fetal tissue) or complete (containing no fetal tissue). They rarely metastasize but they 
may develop into invasive mole or into the more aggressive, rapidly growing, metastatic 
choriocarcinoma. 
In order to investigate the possible cross-talk between PIBF and leptin in regulation 
of trophoblast invasion, paraffin embedded sections from healthy first trimester placentae, 
partial moles, complete moles and choriocarcinomas were analysed by 
immunohistochemistry. Sections were reacted with PIBF, leptin or leptin-receptor specific 
antibodies. 
PIBF was expressed in both normal first trimester villous trophoblast and in partial 
mole, while PIBF expression was markedly decreased in complete mole and absent in 
choriocarcinoma. Neither leptin, nor leptin-receptor was detected in partial mole, whereas 
both of these molecules were present in complete mole and choriocarcinoma (Fig. 7.). 
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FIGURE 7. Immunohistochemical detection of PIBF (A), leptin (B) and leptin-receptor 
(C) expression in healthy 1st trimester trophoblast (1), partial mole (2), complete mole (3) 
and choriocarcinoma (4). (50X) 
 
 
To confirm the inverse relationship between PIBF and leptin/leptin-receptor 
expression, PIBF deficient trophoblast cells were generated with siRNA technique and 
leptin-receptor was detected by Western blotting in normal and PIBF knock down cells 
(Fig. 8.A.). Moreover, leptin expression was detected in the lysates of PIBF-treated cells 
with a protein array (Fig. 8.B.). 
Leptin-receptor expression was upregulated in PIBF deficient cells (Fig. 8.A.), 
while leptin expression was decreased in PIBF-treated cells (Fig. 8.B.), suggesting that 
PIBF controls the expression of leptin and its receptor in the trophoblast. 
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FIGURE 8. PIBF controls trophoblast invasion by down-regulating the expression of 
leptin-receptor (A) and leptin (B). A representative experiment of three is shown. Lysates 
from PIBF knock down and control (scr: scrambled siRNA) HTR-8/SVneo cells were 
reacted with anti-PIBF or anti-leptin-receptor antibodies in Western blotting. Equal loading 
was controlled with anti-β-actin antibody (A, upper panel). Densitometric evaluation of the 
presented Western blots is shown on the lower panel. B: Leptin expression in control and in 
PIBF-treated cells. (Protein array - upper panel; densitometric evaluation of the presented 
spots - lower panel)  
 
 
1.2 The effect of PIBF-knock down on invasion of trophoblast and tumor cell lines 
 
To further investigate the possible role of PIBF in regulating invasion, we used 
trophoblast and tumor cell lines, rendered PIBF deficient by siRNA technique. 
To study trophoblast invasion, HTR-8/SVneo cell line was selected which had been 
generated by transformation of HTR-8 cells with simian virus 40 large T antigen. The 
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primary HTR-8 cultures were obtained after plating and outgrowth of cells from tissue 
pieces of human first trimester villi. The resulting cell line (HTR-8/Svneo) shares 
phenotypic properties with the progenitor cells [122] and its proliferation, migration and 
invasiveness are regulated by the same signaling molecules that modulate extravillous 
trophoblast cell responses in vitro [123-125]. 
 
 
 
FIGURE 9. Immunocytochemical demonstration of PIBF in HT-1080 (A, B) and HTR-
8/SVneo cells (C, D). The cells were reacted with polyclonal anti-48kDa PIBF antibody 
(A, C) or the second antibody only (B, D). 
 
 
For modelling tumor invasion, the highly invasive fibrosarcoma cell line HT-1080 
was selected. Both cell lines express and secrete PIBF (immunocytochemistry, Fig. 9, 
Western blotting, 10.B.) and its receptor (Flow cytometry, Fig. 10.A.). 
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FIGURE 10. A. Flow cytometric analysis of PIBF-receptor expression on the surface of 
HTR-8/SVneo and HT-1080 cells. FITC-conjugated ligand was used to visualize the PIBF-
receptor. B. The supernatants of the cultured cell lines were reacted with anti-PIBF 
antibody (lane 1) or second antibody for control (lane 2). 
 
 
Platypus Oris cell invasion assay (Fig. 6.) was used to determine the invasive 
potential of PIBF knock down HTR-8/SVneo trophoblast and HT-1080 fibrosarcoma cells. 
Silencing of PIBF increased invasivity in HTR8/SVneo cells, and decreased 
invasive behaviour in HT-1080 cells as shown on Fig. 11.A. 
 
 
1.3 PIBF affects the activity of matrix metalloproteinases 
 
Invasion of surrounding tissues is mediated by a set of proteolytic enzymes, among 
others, matrix metalloproteinases (MMPs). MMP-9 and MMP-2 cleave type IV collagen, 
(the main component of basal membranes), thus play a crucial role in trophoblast and tumor 
invasion. 
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Cell conditioned media from the invasion assay were subjected to gelatine 
zymography to measure MMP-2 and MMP-9 activity. In trophoblast cells, PIBF silencing 
resulted in increased MMP-2 and MMP-9 secretion; while PIBF knock down tumor cells 
showed reduced levels of secreted MMP-2 and MMP-9 matrix metalloproteinases (Fig. 
11.B.). 
 
 
 
FIGURE 11. A: Invasion of HTR-8/SVneo and HT-1080 cells after silencing of PIBF. 
Detection zones (3 mm in diameter) in which the seeded sells invaded are shown on the 
confocal images 72 hours after removing the Cell Seeding Stoppers. Cells were stained 
with Calcein AM dye. Invasion assays were repeated at five times. (scr: scrambled siRNA) 
B: Supernatants from the OrisTM Assay were subjected to gelatine zymography to detect 
MMP-2 and -9. A representative experiment is shown on the upper panel. Densitometric 
evaluation of three zymograms are shown on the lower panel. Data are represented as mean 
± SEM. In trophoblast cell line HTR-8/Svneo, silencing of PIBF resulted in increased 
production of MMP-2 and MMP-9 and increased invasion. In tumor cell line HT-1080, 
knock down of PIBF had an opposite effect: production of MMP-2 and 9 as well as 
invasion was decreased. 
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Lysates of PIBF-treated and control samples were analysed by protein arrays 
(Fig.12.). After 24 h PIBF treatment MMP-9 expression increased in fibrosarcoma cells 
while decreased in trophoblast cells. TIMP-1 - which has the capaity to inhibit MMP-9 - 
was downregulated in tumor cells while in trophoblast cells its level increased after 24 h 
PIBF treatment. These findings coincide well with the results of gelatin zymography. 
 
 
 
FIGURE 12. MMP-9 and TIMP-1 expression in PIBF-treated (24 h) trophoblast and 
fibrosarcoma cells was analysed by protein arrays. In tumor cells MMP-9 expression was 
increased and TIMP-1 expression was reduced after 24 h PIBF treatment whereas in 
trophoblast cells MMP-9 expression was decreased and TIMP-1 was increased after PIBF 
treatment. A representative experiment is shown. 
 
 
To sum up, PIBF down-regulates MMP-2,-9 secretion, up-regulates TIMP-1 
expression thus decreases invasion of trophoblast cells; while it facilitates the production of 
MMP-2,-9 and inhibites the secretion of TIMP-1 thus increases invasion in tumor cells. 
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2. PIBF-induced signaling networks and invasive behaviour 
 
 
2.1 Characterization of PIBF-receptor 
 
2.1.1. PIBF-receptor associates with IL-4Rα 
 
Earlier we showed that the engaged PIBF receptor associates with the α-chain of the 
IL-4 receptor for signaling. To further verify the involvement of IL-4R in PIBF signaling, 
IL-4Rα deficient cells were created by siRNA technique. Silencing of IL-4Rα by siRNA 
reduced the STAT6 activating effect of PIBF in peripheral lymphocytes (Fig. 13.), 
confirming that the α-chain of the IL-4 receptor was indeed indispensable for PIBF 
signaling. 
 
 
 
FIGURE 13. Silencing of IL-4Rα reduced the STAT6 activating effect of PIBF in 
lymphocytes. Lysates from IL-4Rα knock down and control cells were reacted with anti-
phospho-STAT6 antibody on Western blot. Loading was controlled by reactivity with anti-
STAT6 antibody. NT=untreated. 
 
 
Capping experiments were performed to detect co-localization and co-capping of 
IL-4R and PIBFR on peripheral blood mononuclear cells. 
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When FITC-labelled PIBF is added to the cells, it binds to the PIBF-receptor, and 
might induce complex formation of the PIBF receptor and IL-4R. Receptor cross-linking 
by anti IL-4R specific antibody might also induce complex formation. To investigate 
these effects, both antibody- and ligand-induced cross-linking was performed. 
 
 
 
FIGURE 14. Confocal microscopy analysis to investigate the complex formation of IL-
4R and the PIBF-receptor (100x). Both anti-IL-4R antibody induced cross-linking (A) 
and ligand-induced capping (B) resulted in co-localization and co-capping of the two 
binding sites. 1: FITC-PIBF labelled PIBFR; 2: PE-anti IL-4R-labelled IL-4R; 3: merged 
picture. C: Simultaneous labelling of lymphocytes with PE-antiCD45RA (red), cross-
linked by anti-mouse IgG1-PE (1) and FITC-PIBF (green) (2), resulted in capping of the 
CD45RA molecule but no co-capping of the PIBFR (3). D: All steps were performed at 
4°C. (All confocal images were taken with identical settings and at least 50 cells were 
counted in each slide. In each experiment more than 90% of the capped cells showed the 
indicated phenotypes.) 
 
 
Antibody-induced cross-linking by anti-IL-4R and PE-conjugated anti-IgG2A+B at 
37ºC results in capping of the IL-4R and simultaneus co-capping of the PIBF receptor, as 
shown on Fig. 14.A. No capping occurred, when all steps were performed at 4°C (Fig. 
14.D.). 
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Ligand-induced cap-formation (Fig. 14.B.) was tested by incubating the cells with 
FITC-PIBF at 37°C. After ligand binding, the cells were fixed and incubated with anti-IL-
4R-PE at room temperature. It was found that PIBF ligand induced capping resulted in co-
capping of the IL-4R. 
To test the specificity of co-capping induced by PIBF ligand or IL-4R specific 
antibody, simultaneous labelling of CD45RA and PIBF receptor was performed. Antibody-
induced CD45RA crosslinking resulted in capping of the CD45RA molecule but no co-
capping with the PIBFR, as shown on Fig. 14.C. 
These data suggest that the PIBF receptor forms a complex with IL-4R and this 
process is initiated by PIBF binding. 
Competition between IL-4 and PIBF was also tested. JAK3 is present on the γ-chain 
of the IL-4R, thus IL-4 signaling involves JAK3 phosphorylation (Fig. 15.A.). In the 
presence of PIBF, IL-4 induced JAK3 phosphorylation was reduced in a concentration-
dependent manner, confirming that the PIBF-receptor is capable of replacing the γ-chain of 
IL-4R (Fig. 15.B). 
 
 
 
FIGURE 15. A: Type I. IL-4R consists of IL-4Rα and the common γ-chain and binds IL-4. 
Upon ligation, the GPI-anchored PIBF-receptor combines with IL-4Rα. B: PIBF-receptor 
replaces the γ-chain in the IL-4 receptor. The lysates of lymphocytes treated with increasing 
PIBF concentrations in the presence of equal concentration of IL-4 were reacted on 
Western blots with anti-phospho-JAK3 antibody. Loading was controlled by anti-actin 
reactivity. A representative experiment of three is shown. 
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2.1.2 The PIBF receptor is a raft-associated, GPI-anchored protein 
 
The above findings raise the question, why IL-4R is needed for PIBF signaling. A 
plausible explanation would be that the PIBF receptor has no transmembrane and 
intracellular domains thus it uses the intracellular tail of IL-4R for signal transduction. 
Assuming that the PIBF receptor is a GPI-anchored protein, we digested the 
putative anchoring-region with phosphatidylinositol-specific phospholipase C (PI-PLC). 
PIBF-induced phosphorylation of STAT6 molecules was tested by Western blotting in 
intact and in PI-PLC digested lymphocytes. 
In PI-PLC digested lymphocytes, PIBF did not induce STAT6 phosphorylation 
while IL-4 retained its effect (Fig. 16.A.), indicating that PIBFR is indeed a GPI-anchored 
molecule. 
Furthermore, capping of IL-4R could still be induced in PI-PLC digested 
lymphocytes but labelling of PIBF receptor was lost (Fig. 16.B.). 
 
 
 
FIGURE 16. A: PIBFR is a GPI-anchored protein. Digestion with PI-PLC cleaves the 
anchoring regions of GPI-anchored PIBFR and results in loss of PIBF induced STAT6 
activation while the effect of IL-4 remains intact. A representative experiment of three is 
shown. (Western blot: anti-phospho-STAT6 Ab, loading: anti-STAT6 Ab. NT: untreated 
cells.) B: Capping of the IL-4Rα (1) in PI-PLC digested cells in the absence of PIBF-
receptor (2). Confocal microscopy, 100x. 
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GPI-anchored proteins are enriched in the leukocyte membrane within 
glycosphyngolipid-cholesterol rafts. These submicron domains need cholesterol to 
function, therefore the hypothesis that receptors of PIBF float in lipid rafts was tested by 
depletion of cholesterol, using methyl--cyclodextrin (MβCD). 
The STAT6 inducing effect of PIBF was abolished in MβCD-treated lymphocytes 
in a concentration-dependent manner. In MCD treated cells neither PIBF, nor IL-4 was 
able to Tyr-phosphorylate STAT6 (Fig. 17.), suggesting that not only the PIBF receptor but 
also the  chain of the IL-4 receptor might be raft-associated. 
 
 
 
FIGURE 17. Disruption of raft integrity by MβCD abrogates PIBF and IL-4 induced Tyr-
phosphorylation of STAT6, suggesting that PIBFR and IL-4R are associated with lipid 
rafts. Western blot: anti-phospho-STAT6 Ab. Loading: anti-STAT6 Ab. NT: untreated 
cells. The experiment was repeated at three times. 
 
 
2.1.3. Internalization of PIBF-receptor  
 
Since the GPI-anchored receptors were found to cluster and recycle at the cell 
surface, we examined the effect of ligand-binding on PIBFR internalization by confocal 
microscopy. Lymphocytes were labeled with FITC-conjugated PIBF and incubated at 37°C 
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for 0, 15, 30 or 60 min (Fig. 18.). Internalization was detectable after 15 min and reached 
the maximum at 60 min. 
 
 
 
FIGURE 18. Internalization of PIBF-receptor starts within 15 minutes after adding its 
ligand at 37°C. Confocal microscopy, 60x oil immersion. Nuclei: Hoechst stained. PIBFR 
was visualized with FITC-labeled PIBF. 
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2.2 PIBF-induced signaling pathways which might affect invasive behaviour 
 
Silencing of IL-4Rα abrogated the effect of PIBF on invasion in both cell lines, 
suggesting, that the invasion-related signaling of PIBF is initiated by the IL-4Rα/PIBFR 
complex (Fig. 19.). 
 
 
 
FIGURE 19. Invasive behaviour of IL-4Rα knock down HTR-8/SVneo and HT-1080 cells. 
IL-4Rα knock down abrogated the effect of PIBF on invasion in both cell lines. (Confocal 
microscopy, 20x.) 
 
 
The next purpose included identifying the signaling networks that might be involved 
in PIBF regulated invasion. Based on the fact, that the GPI-anchored PIBF receptor forms a 
complex with IL-4Rα and uses its intracellular tail for signaling, we focused on IL-4Rα 
associated cascades that might be induced by PIBF (Fig. 20.). 
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IRS, associated with IL-4Rα, can activate the Akt and ERK pathways. Both of these 
play a role in controlling invasive differentiation of trophoblast cells and promote 
metastatic potential of tumors. Therefore, the effect of PIBF treatment on phosphorylation 
of ERK and Akt were investigated in HTR-8/SVneo and HT-1080 cells by Western 
blotting. 
 
 
 
FIGURE 20. IL-4Rα associated signaling pathways that might be activated by PIBF. 
 
 
In trophoblast cells PIBF phosphorylated Akt and ERK in a fast, transient way, 
whereas, in the tumor cell lines PIBF treatment resulted in sustained and late activation of 
Akt and ERK molecules (Fig. 21, 23.). 
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FIGURE 21. In trophoblast cells PIBF phosphorylates Akt (A) and ERK (B) in a fast, 
transient way while in HT-1080 fibrosarcoma cell line PIBF treatment resulted in sustained 
activation of these molecules. Densitograms of the presented Western blots are shown. 
Each sample is normalized with its actin pair. 
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Since many papers reported STAT3 as a key molecule in trophoblast and tumor 
invasion, we also investigated the effect of PIBF treatment on STAT3 Ser727 and Tyr705 
phosphorylation in the same cell lines. 
 
 
 
FIGURE 22. In trophoblast cells PIBF treatment decreased Ser727-phosphorylation of 
STAT3 and did not affect the Tyr 705 phosphorylation of STAT3. PIBF treatment resulted 
in late phosphorylation of both Ser727 and Tyr705 residues of STAT3 in HT-1080 
fibrosarcoma cell line. Densitograms of the presented Western blots are shown. Each 
sample is normalized with its actin pair. 
 
 
In trophoblast cells PIBF did not significantly alter the level of Tyr-phosphorylated 
STAT3 and decreased the amount of Ser-phosphorylated STAT3 molecules after 24 hours 
treatment (Fig. 22, 23.). In tumor cells PIBF treatment resulted in late STAT3 Ser and Tyr 
phosphorylation suggesting an indirect role of PIBF in STAT3 induction. 
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FIGURE 23. The effect of PIBF treatment on Akt, ERK and STAT3 phosphorylation in 
trophoblast and fibrosarcoma cells. Statistical analysis of Western blots from three different 
experiments are shown. Data are represented as mean relative density ± SEM. 
 
 
Finally, we examined whether PIBF treatment alters the level of Wnt5a molecules 
which has been shown to be involved in invasion of many tumors [126,127]. 
In HT-1080 fibrosarcoma cells PIBF induced the activation of Wnt5a molecules 
after 6 hours incubation thus we analysed the Wnt5a signaling pathways in tumor cells in a 
more detailed fashion (Fig. 24.). 
In fibrosarcoma cells the level of β-catenin was reduced with 60% after 6 h PIBF 
treatment suggesting that Wnt5a inhibits the canonical, β-catenin-mediated pathway. 
Moreover, after 6h PIBF treatment PKCζ and PKCδ [128] - the two isoforms which might 
be involved in the non-canonical signaling processes of Wnt5a - were also phosphorylated.  
 PKCδ might be associated with Wnt5a signaling or apoptosis. Nuclear localisation 
of PKCδ is required for its apoptotic function [129], while membrane-association of PKCδ 
shows its involvement in Wnt5a signaling [130]. 
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FIGURE 24. After 6 h PIBF treatment the increased Wnt5a induces the degradation of β-
catenin and signals with the help of PKCζ and PKCδ. Densitograms of the presented 
Western blots are shown. Each sample is normalized with its actin pair. Experiments were 
repeated at three times. 
 
 
To confirm that PKCδ is associated with Wnt5a signaling and not with the apoptotic 
pathway, confocal microscopy was performed to detect the subcellular localization of 
phosphorylated PKCδ after 6h PIBF treatment and cells were Annexin stained to detect 
early signs of apoptosis (Fig. 25.). Phospho-PKCδ was associated with the membrane after 
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6 h treatment supporting the hypothesis that it has a role in Wnt5a signaling. Significant 
apoptosis was not detectable after 6 h PIBF treatment (data not shown). 
 
 
 
FIGURE 25. Subcellular localisation of phospho-PKCδ after 6h PIBF treatment in HT-
1080 cells. Phospho-PKCδ was visualized by anti-phospho-PKCδ Ab and further stained 
with Cy-3-conjugated anti-rabbit Ig; nuclei were labelled by Hoechst. Confocal 
microscopy, 60x oil immersion. 
 
 
 
2.3. Subcellular localization of PIBF 
 
The late signaling events observed in tumor cells are not likely to be due to direct 
PIBF action, rather to that of new PIBF-induced proteins. The full-length PIBF contains 
leucine-zippers, nuclear localization signals and bZIP motives, which enable the molecule 
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to bind to DNA and regulate gene transcription (Fig. 4.). If PIBF induces proteins which 
bind to growth factor receptors, further signal pathways might be activated. 
 
 
 
FIGURE 26. Subcellular localization of PIBF in HTR-8/SVneo (1) and HT-1080 (2) and 
cells by confocal microscopy. A: Merged images of nucleus staining (Hoechst, shown as 
blue) and labeling of PIBF (shown as red; 1st Ab: anti-PIBF, 2nd Ab: anti-rabbit Ig-Cy3) 
B: Merged images of nucleus staining and the secondary control without the first anti-PIBF 
antibody. Confocal microscopy, 60x oil immersion. 
 
 
To confirm that PIBF enters the nucleus, subcellular localization of PIBF was 
visualized in trophoblast and tumor cell lines by confocal microscopy and in fractionated 
cells by Western blotting. For confocal microscopy PIBF was labelled with the fluorescent 
dye Cy3 and nuclei were counterstained by Hoechst (Fig. 26.). PIBF reactivity was 
detected in the nucleus as well as in the cytoplasm of both cell lines. 
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Then nuclear fraction was isolated from the cells to detect PIBF by Western blotting 
(Fig. 27.). PIBF was present in the nucleus of both cell lines, however, the ratio of nuclear 
versus cytoplasmic PIBF was higher in the tumor, than in the trophoblast cells. 
 
 
 
FIGURE 27. Subcellular localization of PIBF in trophoblast and tumor cell lines. Nuclear 
and cytosol fractions were reacted with anti-48kDa PIBF or anti-exon-17 antibodies by 
Western blotting. A representative experiment of three is shown. 
 
 
 
2.4. PIBF-induced genes 
 
To identify PIBF-induced genes, protein arrays (for detection of 55 angiogenesis- 
and invasion-related molecules) were performed on lysates of PIBF-silenced and 24 h 
PIBF-treated trophoblast and fibrosarcoma cells. In PIBF knock down tropoblast cells, no 
significant alteration was found, suggesting that in trophoblast cells PIBF does not induce 
the genes of the tested proteins and the events are due to by receptor-mediated effects of 
PIBF. 
In fibrosarcoma cells PIBF induced the transcription of HB-EGF, PlGF, FGF-1, 
endothelin-1 and angiogenin (Fig. 28.). Either of these can initiate the observed late 
signaling pathways. 
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To confirm this possibility, we investigated the effect of PIBF treatment on STAT3 
activation in HB-EGF silenced HTR-8/SVneo and HT-1080 cells. In HB-EGF knock down 
fibrosarcoma cells the STAT3-activating effect of PIBF was reduced compared to the 
control (scrambled) suggesting that late STAT3 activation might have been caused by 
PIBF-induced HB-EGFF (Fig. 29.). 
 
 
 
FIGURE 28. After silencing of PIBF, HT-1080 cells were analysed by protein arrays. 
PIBF induced angiogenin, endothelin-1, HB-EGF, PlGF, FGF-1 production. A 
representative experiment is shown. 
 
 
IL-6 is also an important activator of STAT3 signaling pathway. Therefore, secreted 
IL-6 was measured in the supernatants of PIBF silenced trophoblast and fibrosarcoma cells 
by cytometric bead array. IL-6 production was increased in PIBF knock down trophoblast 
cells compared to the control sample, whereas IL-6 secretion of PIBF-silenced HT-1080 
cells was reduced, suggesting that PIBF might regulate IL-6 expression (Fig. 30.). 
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FIGURE 29. STAT3 activation by 24 h PIBF treatment in HB-EGF-silenced HT-1080 
cells. Densitogram of the presented Western blots is shown. Each sample is normalized 
with its actin pair. A representative experiment of three is shown. 
 
 
 
FIGURE 30. IL-6 secretion of intact and PIBF knock down trophoblast and fibrosarcoma 
cells. Silencing of PIBF resulted in increased IL-6 secretion in trophoblast- and decreased 
IL-6 secretion in tumor cells. Data are represented as mean ± SEM. (n=3/group)  
 
 
59 
 
We also investigated the effect of PIBF knock down on Wnt5a expression. After 
silencing of PIBF, the levels of Wnt5a decreased in tumor cells and increased in trophoblast 
cells suggesting that Wnt5a might be a PIBF-regulated gene (Fig. 31.). 
 
 
 
FIGURE 31. Wnt5a expression in intact and PIBF knock down trophoblast and 
fibrosarcoma cells. Western blots of a representative experiment are shown together with 
their densitogramic evaluation. Each sample is normalized with its actin pair. (scr: 
scrambled siRNA) 
 
 
To verify that PIBF is capable to regulate the transcription of these molecules, 
chromatin immunoprecipitation (ChIP) was performed with anti-PIBF antibody. During 
testing the possible promoter-binding sites for PIBF by the primers shown in Table 3., 
ChIP assay revealed that PIBF has the capacity to bind to the promoter of Wnt-5a and EGF 
both in trophoblast cells (not shown) and fibrosarcoma cells (Fig. 32.). 
The protein profile of the protein/DNA complex precipitated by anti-PIBF antibody 
was different in HTR-8/SVneo tophoblast and HT-1080 fibrosarcoma cells: in trophoblast 
cells the 50-kDa and 67-kDa PIBF isoforms were present in the complex while in 
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fibrosarcoma cells the complex also included the full-length PIBF isoform (Fig. 33.) 
suggesting that the composition of the transcription complexes are different in trophoblast 
and tumor cells and regulate gene expression in a tissue specific manner. 
 
 
FIGURE 32. Chromatin Immunoprecipitation from HT-1080 cells shows that PIBF might 
bind to the promoter region of EGF and Wnt5a genes. 
 
 
 
FIGURE 33. Western blot analysis of protein complex immunoprecipitated by anti-PIBF 
(ChIP). In trophoblast cells the complex contains the 50- and 67-kDa PIBF isoforms, while 
in tumor cells the 90-kDa isoform is also included in the complex. 
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VI. DISCUSSION 
 
 
During the first trimester of pregnancy, trophoblast cells invade the uterine tissue 
and vessels in an invasive and eroding manner and establish the foundation of human 
pregnancy and foetal development. Invasive trophoblasts anchore the placenta to the uterine 
wall, modulate implantation as well as secretion of hormones and cytokines and most 
importantly play a crucial role in remodelling of maternal spiral arteries. The latter is 
required to increase blood flow to the placenta to provide sufficient oxygen and nutrient 
supply for the developing fetus [131]. 
Invasiveness is a common feature of trophoblast and malignant tumors. Embryo 
implantation is similar to the growth of cancer cells. Similarly to tumor invasion of the host 
tissue, trophoblast invasion of the uterus is a multi-step process. It involves attachment of 
the trophoblast cells to the extracellular matrix (ECM) components, degradation of the 
ECM and migration through the eroded connective tissue. However, unlike tumor invasion, 
trophoblast invasion is precisely regulated. It is limited in space and only possible during 
the implantation window (6th - 9th day after fertilization in humans). 
 Among others, progesterone and progesterone-induced genes possess a crucial role 
during implantation via governing trophoblast invasion. Progesterone decreases invasion 
and gelatinase expression in early first trimester trophoblast cells [132]. 
 Progesterone-Induced Blocking Factor was first described as a progesterone-
induced molecule that mediates the immunological effects of progesterone. Recently, PIBF 
has also been found in rapidly proliferating cells, malignancies and in the trophoblast. This 
raised the question wheather PIBF is involved in regulation of invasion. To investigate this, 
we used an extravillosus trophoblast cell line (HTR-8/SVneo) and tumor cell lines (e.g. 
HT-1080) as model. 
 PIBF-silenced HTR-8/SVneo cells showed increased invasivity together with 
increased MMP-9, MMP-2 and decreased TIMP-1 activation while knocking down of PIBF 
in the tumor cell line resulted in decreased invasive potential as well as decreased MMP-9,  
MMP-2 and increased TIMP-1 activity (Fig.34.). These findings confirm that PIBF is 
involved in invasion and matrix remodelling by altering the activity of gelatinases (MMP-9 
62 
 
and MMP-2). The data also suggest a different role of PIBF in trophoblast and tumor 
invasion. 
 
 
 
FIGURE 34. The role of PIBF in regulation of invasion. In trophoblast cells PIBF is 
responsible for decreased production of MMP-9, MMP-2 and increased production of 
TIMP-1, suggesting its role in controlling trophoblast invasion. PIBF induces MMP-9, 
MMP-2 activity and inhibits TIMP-1 expression in fibrosarcoma cells, thus facilitates 
invasion. 
 
 
 These data are in line with the finding that progesterone suppresses the production 
of MMP-9 during the implantation period. To explore the underlying mechanisms, we first 
characterized the PIBF-receptor.  
Both HTR-8/SVneo and HT-1080 cells express PIBF-receptors on their surface and 
secrete PIBF, thus autocrine regulation of PIBF is possible. Many transformed cells 
continuously produce both growth factors and their receptors, thereby providing themselves 
an auto-stimulatory growth impulse. Autocrine regulation of the human trophoblast has 
also been described, for instance, via the VEGF/VEGF-receptor system. [66, 72]. 
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 We showed that the PIBF-receptor is a GPI-anchored, lipid-raft associated protein 
that can form a heterodimer with IL-4Rα and uses the intracellular domain of the latter for 
signaling. 
 IL-4 is able to induce Akt [133-135] and ERK [136-138] and these molecules might 
be involved in invasion and tumorigenesis [139-140] thus we tested wheather PIBF can 
activate these pathways. In trophoblast cells PIBF activated Akt and ERK molecules 
transiently (at 20 min), while in the tested tumor cells sustained Akt and ERK 
phosphorylation was observed. 
 STAT3 phosphorylation was also investigated in these cells since it is a key player 
in invasion [87-90]. In trophoblast cells Ser-phosphorylation of STAT3 was inhibited after 
PIBF treatment, while in tumor cells we experienced late activation of STAT3 (both Ser 
and Tyr phosphorylation) transcription factors after 6 and 24 hours PIBF treatment. 
Wnts have a role in cancer progression, furthermore, they are implicated in 
implantation and early trophoblast developement as well as in pathogenesis of trophoblastic 
diseases. Recent studies reported that various Wnts (Wnt5a, Wnt11) are detectable in the 
pre-implanting embryo and a shift was demonstrated from non-canonical signaling in the 
pre-implantation period towards canonical signaling in activated blastocysts during 
implantation [141]. 
Dickkopf-related protein-1 (Dkk1), a major secreted Wnt signaling antagonist is up-
regulated by progesterone in the endometrium during the implantation window, 
furthermore, progesterone-dependent induction of Dkk1 inhibited Wnt signaling [142-143], 
suggesting that repression of the pathway plays a role in decidualisation.  
Wnt5a has distinct roles in development and tissue homeostasis. Recent data point 
to a critical role of Wnt5a in malignant progression, but its role is controversial: Loss of 
Wnt5a signaling is related to development of lymphoid malignancies, whereas 
constitutively active Wnt5a signaling is involved in invasion or metastasis of several 
cancers [127, 144]. 
Wnt5a is thought to primarily signal through non-canonical pathways. The 
Wnt5a/PKC pathway mediates motility and initiates an epithelial to mesenchymal 
transition [145]. 
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In tumor cells, 6h PIBF treatment resulted in Wnt5a activation together with 
reduced β-catenin levels, suggesting that the canonical Wnt pathway is inhibited. 
Moreover, 6 hours PIBF treatment increased PKCζ and PKCδ phosphorylation. PKCζ is 
known to be involved in non-canonical Wnt5a signal transduction.  
 
 
 
FIGURE 35. A: Canonical Wnt signaling pathway. In the presence of the Wnt molecule, 
Dvl inhibits GSK3β and β-catenin translocates to the nucleus and induces the transcription 
of the target genes. B: PIBF induced non-canonical Wnt5a signaling pathway. A possible 
signaling event in HT-1080 fibrosarcoma cells: 6h PIBF treatment induces Wnt5a and 
phosphorylation of PKCδ and PKCζ while β-catenin is degraded. Wnt5a supports invasion 
via non-canonical pathways with the help of PKCζ and PKCδ. 
 
 
PKCδ might be associated with Wnt5a signaling or apoptosis. Nuclear localisation 
of PKCδ is required for its apoptotic function while membrane-association of PKCδ shows 
its involvement in Wnt5a signaling [129, 130]. To assess the function of PKCδ in PIBF 
induced signaling, PIBF-treated fibrosarcoma cells were analyzed for PKCδ localization by 
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confocal microscopy. After 6 h PIBF treatment, PKCδ was found to be membrane-
associated suggesting its role in Wnt5a induced signaling. Moreover, 6 h PIBF treatment 
did not result in early signs of apoptosis (Annexin staining).  
In summary, PIBF induced Wnt5a inhibits the canonical Wnt pathway by promoting 
degradation of β-catenin and signals via non-canonical mechanisms in which PKCζ and 
PKCδ are involved (Fig.35.). 
 The sustained activation of Akt and Erk, the late STAT3 phosphorylation and 
Wnt5a activation in tumor cells suggest that in addition to the receptor-mediated effects of 
PIBF there might be other mechanisms with which PIBF participates in invasion. 
Since PIBF possesses NLS, LeuZip and bZIP sequences, we analysed the 
subcellular localisation of PIBF. PIBF was present not only in the cytoplasm but also in the 
nucleus thus it is conceivable that PIBF induces genes which might be responsible for the 
experienced sustained and late signaling events in case of tumor cells. 
 Lysates of PIBF-silenced trophoblast and fibrosarcoma cells were analysed with 
protein arrays for 55 invasion and angiogenesis related molecules. In PIBF knock down and 
control trophoblast cells there were no significant alterations between the levels of the 
tested invasion and angiogenesis related proteins. 
 In PIBF silenced fibrosarcoma cells the expression of bFGF, HB-EGF, PlGF, 
angiogenin and endothelin-1 were reduced, supporting the hypothesis that PIBF might 
induce the genes of these growth factors and angiogenesis associated molecules. 
 In order to confirm, that late PIBF signaling was indeed due to gene induction, HB-
EGF knock down fibrosarcoma cells were created. In these cells the STAT3 activating 
effect of PIBF was reduced compared to the control. Moreover, IL-6 secretion and Wnt5a 
production of PIBF knock down HT-1080 cells were reduced compared to the control 
sample. In contrast to this, PIBF knock down in trophoblast cells resulted in increased IL-6 
production together with increased Wnt5a and leptin-receptor expression. 
 Finally, chromatin immunoprecipitation with anti-PIBF antibody showed that PIBF 
could bind to the promoter of Wnt5a and EGF both in trophoblast and tumor cells. 
However, while in trophoblast cells the promoter-binding complex contains the 50-kDa and 
67-kDa PIBF isoforms, in tumor cells the full length PIBF is also included in the 
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transcription complex (Fig.36.). The differential effect of PIBF might be due to this 
difference. 
 
 
 
FIGURE 36. PIBF binds to the promoter regions of certain genes. In fibrosarcoma cells 
PIBF induces FGF, HB-EGF, PlGF and Wnt-5a while in trophoblast cells there is no gene 
induction. 
 
 
In conclusion, in tumor – but not in trophoblast – cells PIBF promotes invasion by 
gene activation, e.g., that of EGF, IL-6, Wnt5a. The secreted proteins (IL-6, EGF) bind 
then to their own receptors and induce Akt, ERK and STAT3 phosphorylation which in 
turn further activates transcription of invasion promoting molecules (e.g. MMP-9, MMP2). 
(Fig.37.) 
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FIGURE 37. Signaling pathways that lead to PIBF-induced invasion in HT1080 
fibrosarcoma cells.  
 
 
 
Based on our findings, it can not be ruled out, that PIBF suppresses the transcription 
of leptin-receptor, IL-6 and Wnt5a genes in trophoblast cells and as an intrinsic control 
molecule negatively regulates trophoblast invasion. In line with this, in choriocarcinoma, 
the loss of PIBF results in increased invasive behaviour since the genes (leptin-receptor, IL-
6, Wnt5a) normally suppressed by PIBF will be transcribed (Fig.38.). 
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FIGURE 38. In trophoblast cells PIBF might suppress the genes of leptin-receptor, HB-
EGF, Wnt5a and IL-6. In the absence of PIBF-mediated inhibition these genes will be 
activated. 
 
 
 Our data provide evidence that PIBF is not only responsible for modulating the 
immunological effects of progesterone but it also has a vital role in tumor invasion as well 
as in controlling trophoblast invasion at a physiological level. Invasion is known to be 
closely associated with angiogenesis. Preliminary data from our laboratory suggest that 
PIBF might affect the production of angiogenic factors (e.g. VEGF, angiogenin etc.) and in 
lymphocytes increases the expression and phosphorylation of tumor suppressor molecules 
(e.g. p53). The precise signaling events of these processes need to be further investigated. 
 These findings might be implemented in therapeutical approaches. Designing 
receptor agonists might be a promising anti-abortive therapy in those pregnancies which are 
characterized by low PIBF levels and receptor antagonists or PIBF inhibitors might be 
useful in the treatment of PIBF-positive tumors. 
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VII. SUMMARY OF THESES 
 
 
I. PIBF is implicated in the regulation of both trophoblast and tumor invasion. 
II. In trophoblast cells PIBF down-regulates the expression of the pro-invasive leptin 
and its receptor, suggesting that PIBF might be involved in the control of 
trophoblast invasion. 
III. In the normal trophoblast  partial mole  complete mole  choriocharcinoma 
transition there is a shift towards uncontrolled invasive behaviour characterized by 
gradual loss of PIBF and an increasing leptin/leptin-receptor expression pattern, 
suggesting an inverse relationship between PIBF and leptin/leptin-receptor 
expression. 
IV. In trophoblast, the lack of PIBF is associated with increased invasion, suggesting 
that PIBF regulates the physiological trophoblast invasion. In HT-1080 tumor cells 
PIBF knock down results in restricted invasion suggesting that PIBF might facilitate 
invasive behaviour of tumor cells. 
V. PIBF takes part in matrix remodelling by altering the activity of MMP-9 and MMP-
2 matrix metalloproteinases. In trophoblast cells, silencing of PIBF induces the 
secretion of gelatinases (i.e. MMP-9 and MMP-2) and inhibits TIMP-1 expression, 
while in fibrosarcoma cells downregulation of PIBF results in decreased gelatinase 
activity together with increased TIMP-1 level. 
VI. HTR-8/SVneo and HT-1080 cells secrete PIBF and express PIBF-receptors on their 
surface, thus autocrine regulation of PIBF is a possibility. 
VII. PIBF is capable to activate the Akt and ERK pathways via binding to the PIBF-
receptor/IL-4Rα heterocomplex in both trophoblast and fibrosarcoma cells.  
VIII. In trophoblast cells the effect of PIBF on Akt and ERK phosphorylation is transient, 
while in fibrosarcoma cells PIBF induces sustained activation of these molecules. 
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IX. In trophoblast cells PIBF inhibits Wnt5a activation and Ser-phosphorylation of 
STAT3 and it does not alter STAT3-Tyr phosphorylation. 
X. In HT-1080 tumor cells PIBF induces late activation of Wnt5a and late 
phosphorylation of STAT3 (both Tyr and Ser) molecules. 
XI. In HT-1080 cells after 6 h PIBF treatment the amount of β-catenin is reduced while 
PKCζ and PKCδ isoforms are activated together with Wnt5a, suggesting that Wnt5a 
inhibits the canonical pathway and might use these two PKC isoforms for signaling. 
XII. In trophoblast and HT-1080 tumor cells PIBF is present in the nucleus. 
XIII. In fibrosarcoma cells PIBF might activate molecules involved in invasion and 
angiogenesis (e.g. FGF-1, HB-EGF, IL-6, PlGF, endothelin and angiogenin etc.) at 
the gene level as a transcription factor. 
XIV. PIBF is capable to bind specifically to certain promoter regions, among others, to 
the promoter of Wnt5a and EGF in both trophoblast and fibrosarcoma cells. 
XV. Silencing of PIBF results in reduced Wnt5a and IL-6 production in fibrosarcoma 
cells. In contrast to this, Wnt5a and IL-6 expression is increased in PIBF knock 
down trophoblast cells. These data suggest that PIBF might induce the transcription 
of Wnt5a and IL-6 genes in fibrosarcoma cells, while PIBF might suppress the 
transcription of Wnt5a and IL-6 genes in trophoblast cells. 
XVI. The differential effect of PIBF might reside in the composition of the protein 
complex which binds to the promoter region of the above mentioned genes. While 
in trophoblast cells the promoter-binding complex contains the 50-kDa and 67-kDa 
PIBF isoforms, in tumor cells the full length PIBF is also included in the 
transcription complex. 
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